Schwab Charles Investment Management Inc. grew its stake in shares of Teladoc, Inc. (NYSE:TDOC) by 34.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 198,264 shares of the health services provider’s stock after acquiring an additional 50,899 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.36% of Teladoc worth $6,880,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in TDOC. FMR LLC boosted its holdings in shares of Teladoc by 163.5% during the 1st quarter. FMR LLC now owns 8,103,237 shares of the health services provider’s stock valued at $202,581,000 after acquiring an additional 5,028,237 shares during the last quarter. Janus Capital Management LLC purchased a new stake in shares of Teladoc during the 1st quarter valued at about $37,258,000. Vanguard Group Inc. boosted its holdings in shares of Teladoc by 50.0% during the 1st quarter. Vanguard Group Inc. now owns 2,727,079 shares of the health services provider’s stock valued at $68,177,000 after acquiring an additional 909,252 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in shares of Teladoc during the 1st quarter valued at about $18,516,000. Finally, Riverbridge Partners LLC purchased a new stake in shares of Teladoc during the 2nd quarter valued at about $23,392,000.
A number of analysts have recently issued reports on the stock. BidaskClub raised shares of Teladoc from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Piper Jaffray Companies reiterated a “buy” rating and issued a $42.00 price objective on shares of Teladoc in a research note on Friday, July 28th. Chardan Capital increased their price objective on shares of Teladoc from $30.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, June 20th. Cantor Fitzgerald reiterated a “hold” rating and issued a $27.00 price objective on shares of Teladoc in a research note on Monday, June 19th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $33.00 price objective (up previously from $28.00) on shares of Teladoc in a research note on Friday, June 16th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $38.00.
COPYRIGHT VIOLATION NOTICE: “Teladoc, Inc. (TDOC) Stake Increased by Schwab Charles Investment Management Inc.” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/10/09/teladoc-inc-tdoc-stake-increased-by-schwab-charles-investment-management-inc.html.
Teladoc, Inc. (TDOC) opened at 34.35 on Monday. The stock has a 50 day moving average of $33.36 and a 200 day moving average of $33.36. The company’s market cap is $1.95 billion. Teladoc, Inc. has a 52 week low of $14.00 and a 52 week high of $37.55.
Teladoc (NYSE:TDOC) last issued its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.02). The firm had revenue of $44.60 million during the quarter, compared to analysts’ expectations of $44.39 million. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. Teladoc’s quarterly revenue was up 68.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.38) EPS. Equities research analysts predict that Teladoc, Inc. will post ($1.44) EPS for the current fiscal year.
In related news, VP Mark Hirschhorn sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $34.04, for a total value of $340,400.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Adam C. Vandervoort sold 53,806 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.92, for a total value of $1,663,681.52. Following the completion of the sale, the insider now owns 33,008 shares in the company, valued at approximately $1,020,607.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 108,806 shares of company stock worth $3,471,732. 4.47% of the stock is owned by insiders.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc, Inc. (NYSE:TDOC).
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.